Literature DB >> 28000530

Welcome to the 9th Volume of Immunotherapy.

Sonia Mannan1.   

Abstract

Keywords:  allergen immunotherapy; cancer immunotherapy; cancer vaccines; checkpoint inhibitors; immunotherapy

Year:  2017        PMID： 28000530     DOI： 10.2217/imt-2013-0201

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  18 in total

Review 1.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Roger G Owen; Steven P Treon; Ayad Al-Katib; Rafael Fonseca; Philip R Greipp; Mary L McMaster; Enrica Morra; Gerassimos A Pangalis; Jesus F San Miguel; Andrew R Branagan; Meletios A Dimopoulos
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 2.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Robert A Kyle; Steven P Treon; Raymond Alexanian; Bart Barlogie; Magnus Björkholm; Madhav Dhodapkar; T Andrew Lister; Giampaolo Merlini; Pierre Morel; Marvin Stone; Andrew R Branagan; Véronique Leblond
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

3.  Development of EBV-associated diffuse large B-cell lymphoma in Waldenstrom macroglobulinemia and mantle cell lymphoma.

Authors:  Abraham M Varghese; Hazem Sayala; Paul A S Evans; Sheila J M O'Connor; Russell Patmore; Peter Hillmen; Roger G Owen
Journal:  Leuk Lymphoma       Date:  2008-08

Review 4.  Waldenström Macroglobulinemia: Review of Pathogenesis and Management.

Authors:  Seongseok Yun; Ariel C Johnson; Onyemaechi N Okolo; Stacy J Arnold; Ali McBride; Ling Zhang; Rachid C Baz; Faiz Anwer
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-03-07

Review 5.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 6.  Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Authors:  Stephen M Ansell; Robert A Kyle; Craig B Reeder; Rafael Fonseca; Joseph R Mikhael; William G Morice; P Leif Bergsagel; Francis K Buadi; Joseph P Colgan; David Dingli; Angela Dispenzieri; Philip R Greipp; Thomas M Habermann; Suzanne R Hayman; David J Inwards; Patrick B Johnston; Shaji K Kumar; Martha Q Lacy; John A Lust; Svetomir N Markovic; Ivana N M Micallef; Grzegorz S Nowakowski; Luis F Porrata; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Carrie A Thompson; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; Morie A Gertz
Journal:  Mayo Clin Proc       Date:  2010-08-11       Impact factor: 7.616

7.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.

Authors:  Sharon Barrans; Simon Crouch; Alex Smith; Kathryn Turner; Roger Owen; Russell Patmore; Eve Roman; Andrew Jack
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

Review 8.  Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.

Authors:  Prashant Kapoor; Jonas Paludo; Stephen M Ansell
Journal:  Curr Treat Options Oncol       Date:  2016-03

Review 9.  Current challenges and novel treatment strategies in double hit lymphomas.

Authors:  Mary Ann Anderson; Alpha Tsui; Meaghan Wall; David C S Huang; Andrew W Roberts
Journal:  Ther Adv Hematol       Date:  2016-02

10.  Development of diffuse large B-cell lymphoma in a patient with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms.

Authors:  Masayuki Shiseki; Akihiro Masuda; Norimichi Watanabe; Masami Fujii; Tomofumi Kimura; Kentaro Yoshinaga; Naoki Mori; Masanao Teramura; Toshiko Motoji
Journal:  Hematol Rep       Date:  2011-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.